Conference Coverage

Tackling grief, loss in patients with advanced lung cancer


 

Patients with life-limiting advanced lung cancer often experience intense grief and loss.

Addressing patients’ physical symptoms – drug side effects, trouble breathing, pain, fatigue – alongside their psychological and spiritual distress – depression, anxiety, fear of death – is critical to restoring their dignity and improving their quality of life, say palliative care experts.

Palliative care aims “to anticipate, prevent, and reduce suffering, promote adaptive coping, and support the best possible quality of life ... regardless of the stage of the disease or the need for other therapies,” commented Andreas Charalambous, RN, PhD, assistant professor (acting) of oncology and palliative care at the Cyprus University of Technology in Limassol, Cyprus.

He was speaking at the 2021 World Conference on Lung Cancer, where he chaired a special session entitled, “Grief and Loss in Palliative Care.”

Research shows that the use of palliative care is associated with improved quality of life and lower costs of care for patients with cancer. But a 2015 Palliative Care Survey by the National Comprehensive Cancer Network found that although the majority of leading U.S. cancer centers have inpatient palliative care services, most reported insufficient capacity to meet the demand, and that home-based palliative care services and inpatient units were much less common.

Dr. Charalambous emphasized the importance of enhancing the use and quality of palliative care services for patients with advanced lung cancer.

During the session, experts discussed an array of strategies geared towards relieving physical symptoms as well as psychological and spiritual stressors.

Physical activity: Establishing what’s possible

Grief and loss are “natural and normal” reactions to advanced cancer, commented Celia Marston, MPallCare, clinical lead for occupational therapy at Peter MacCallum Cancer Centre in Melbourne, Australia.

Patients experience feelings of loss around their independence, relationships, physical and cognitive functioning, which in turn impacts their sense of identity, daily routines, and plans for the future.

According to Ms. Marston, the rapid physical decline patients experience in the last 3 months of life is particularly “distressing,” which is why helping patients continue to perform everyday tasks is so critical.

In clinical practice, this means providing patients palliative rehabilitation focused on maintaining at least a degree of their normal physical activity, which allows them “to adjust and contend with that decline,” Ms. Marston said. It also requires understanding what is important to patients and supporting those requests.

According to Ms. Marston, optimizing patient function can help maintain or slow that rate of physical decline, or sometimes improve it. But even partial activity can be “equally if not more important” than full participation in an activity. Patients “want to be active, they want to test what they can and can’t do” and establish what is possible, she said.

Nonpharmacological approaches to symptom control

Addressing strategies to relieve physical symptoms in patients with lung cancer, Alex Molassiotis, RN, PhD, chair professor of nursing at Hong Kong Polytechnic University, explored the role nonpharmacological interventions can play.

Dr. Molassiotis highlighted the 2021 American Society of Clinical Oncology guidelines for the Management of Dyspnea in Advanced Cancer, which discuss a range of nonpharmacological strategies to manage respiratory distress, in particular. These include supplemental oxygen and noninvasive ventilation as well as breathing techniques, posture, relaxation, meditation, physical and music therapy, and acupressure or reflexology.

In a 2015 randomized controlled feasibility trial, Dr. Molassiotis explored the effectiveness of one such strategy – inspiratory muscle training – in patients with lung cancer and reported improvements in the respiratory symptom cluster of breathlessness, cough, and fatigue. A 2020 trial of breathing retraining and psychosocial support for managing dyspnea in patients with lung cancer or mesothelioma also showed the intervention improved average dyspnea, control over dyspnea, and anxiety.

However, Dr. Molassiotis cautioned, many other nonpharmacological interventions have only “limited” evidence of effectiveness, and a “stronger evidence base” is required.

Physicians should nevertheless talk to patients about their respiratory symptoms and discuss the available options, taking into account the “major impact” these symptoms have on their quality of life.

Pages

Recommended Reading

Metformin disappoints in two phase 2 lung cancer trials
MDedge Hematology and Oncology
Microwave ablation an alternative therapy in lung malignancy
MDedge Hematology and Oncology
Finding the most bang for the buck with adjuvant atezolizumab for NSCLC
MDedge Hematology and Oncology
Unequal resource distribution underlies lung cancer disparities
MDedge Hematology and Oncology
Air pollution – second leading cause of lung cancer
MDedge Hematology and Oncology
Pandemic strategies to boost trial enrollment should stay
MDedge Hematology and Oncology
COVID is especially dangerous for mesothelioma
MDedge Hematology and Oncology
Combo treatment for NSCLC with brain metastases extends survival by two years for some
MDedge Hematology and Oncology
POSEIDON: Two ICIs plus chemo up survival in mNSCLC
MDedge Hematology and Oncology
ESMO 2021: Impressive clinical research despite pandemic
MDedge Hematology and Oncology